What are the best medications for treating mania and depression in bipolar disorder?

Best Medications for Mania and Depression in Bipolar Disorder

For Acute Mania

Lithium, valproate, or atypical antipsychotics (aripiprazole, olanzapine, risperidone, quetiapine, ziprasidone) are the first-line treatments for acute mania, with lithium being the only FDA-approved agent for patients age 12 and older and showing superior long-term evidence. 1, 2, 3

Medication Selection Algorithm for Mania

Start with lithium as first-line monotherapy unless specific contraindications exist:

• Lithium produces normalization of manic symptoms within 1-3 weeks 3
• Response rates range from 38-62% in acute mania 1
• Lithium is more effective than placebo at inducing response (OR 2.13) and remission (OR 2.16) 4
• Target serum level: 0.8-1.2 mEq/L for acute treatment 1

Alternative first-line options when lithium is unsuitable:

• Valproate: Particularly effective for mixed or dysphoric mania, with response rates of 53% in children and adolescents (higher than lithium's 38%) 1, 5
• Atypical antipsychotics: Provide more rapid symptom control than mood stabilizers alone 1
  • Olanzapine: Probably slightly more effective than lithium (OR 0.44 favoring olanzapine) 4
  • Risperidone: May be more effective than lithium for acute response 4
  • Aripiprazole: Favorable metabolic profile compared to olanzapine 1

For severe or treatment-resistant mania:

• Combination therapy with lithium or valproate PLUS an atypical antipsychotic 1, 2, 5
• Quetiapine plus valproate is more effective than valproate alone 1
• Olanzapine combined with lithium or valproate is more effective than mood stabilizer monotherapy 1

Critical Monitoring for Mania Treatment

Lithium requires:

• Baseline: CBC, thyroid function, urinalysis, BUN, creatinine, serum calcium, pregnancy test 1
• Every 3-6 months: lithium levels, renal and thyroid function, urinalysis 1

Valproate requires:

• Baseline: liver function tests, CBC, pregnancy test 1, 2
• Every 3-6 months: serum drug levels, hepatic function, hematological indices 1

Atypical antipsychotics require:

• Baseline: BMI, waist circumference, blood pressure, fasting glucose, fasting lipid panel 1
• Monthly BMI for 3 months then quarterly; blood pressure, glucose, lipids at 3 months then yearly 1

---

For Bipolar Depression

The combination of olanzapine and fluoxetine is the first-line treatment for bipolar depression, with antidepressants NEVER used as monotherapy due to risk of mood destabilization. 1, 5, 6

Medication Selection Algorithm for Depression

First-line: Olanzapine-fluoxetine combination

• FDA-approved specifically for bipolar depression 6
• Recommended by American Academy of Child and Adolescent Psychiatry 1, 5

Alternative options:

• Lamotrigine: Effective for bipolar depression, particularly in bipolar II disorder 5
  • Approved for maintenance therapy, particularly effective for preventing depressive episodes 1
  • Must be titrated slowly to minimize risk of Stevens-Johnson syndrome 1

If adding an antidepressant:

• ALWAYS combine with a mood stabilizer (lithium or valproate) 1, 5
• SSRIs (particularly fluoxetine) are preferred over tricyclic antidepressants 5
• Antidepressant monotherapy can trigger manic episodes or rapid cycling 1

---

Maintenance Therapy

Continue the regimen that effectively treated the acute episode for at least 12-24 months, with lithium showing superior evidence for prevention of both manic and depressive episodes. 1, 7

Long-Term Treatment Strategy

Lithium is the preferred maintenance agent:

• Only drug shown efficacious in preventing any mood episodes, manic episodes, AND depressive episodes in non-enriched trials 7
• Reduces suicide attempts 8.6-fold and completed suicides 9-fold 1
• More effective at preventing manic/hypomanic episodes than depressive episodes 8

Alternative maintenance options:

• Valproate: As effective as lithium for maintenance therapy 1, 5
• Lamotrigine: FDA-approved for maintenance, particularly for preventing depressive episodes 1, 5
• Olanzapine: FDA-approved for maintenance in adults 5

Critical warning: Withdrawal of maintenance lithium therapy increases relapse risk, especially within 6 months of discontinuation, with >90% of noncompliant adolescents relapsing versus 37.5% of compliant patients 1

---

Common Pitfalls to Avoid

• Never use antidepressant monotherapy - triggers mania or rapid cycling 1, 5
• Inadequate treatment duration - conduct 6-8 week trials at adequate doses before concluding ineffectiveness 1
• Premature discontinuation - maintain therapy for minimum 12-24 months after acute episode 1
• Failure to monitor metabolic effects - particularly with atypical antipsychotics causing weight gain, diabetes, dyslipidemia 1, 2
• Overlooking comorbidities - substance use disorders, anxiety disorders, or ADHD complicate treatment 1

Special Considerations for Women

Avoid valproate in women of childbearing potential when possible:

• Teratogenic risk 2
• Associated with polycystic ovary disease 1, 2
• Pregnancy testing required before initiating treatment 2